Reuters logo
BRIEF-FDA grants Alnylam breakthrough therapy designation for Patisiran
November 20, 2017 / 12:10 PM / a month ago

BRIEF-FDA grants Alnylam breakthrough therapy designation for Patisiran

Nov 20 (Reuters) - Alnylam Pharmaceuticals Inc

* U.S. Food and Drug Administration (FDA) grants Alnylam breakthrough therapy designation (BTD) for Patisiran for the treatment of hereditary ATTR (HATTR) amyloidosis with polyneuropathy

* Alnylam Pharmaceuticals Inc - ‍Alnylam has initiated a rolling new drug application (NDA) for Patisiran and expects last submission by end of 2017​

* Alnylam - ‍co, in alliance with Sanofi Genzyme, intends to file a marketing authorization application in European Union around year-end for Patisiran​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below